The σ₁ receptor is a transmembrane protein implicated in several pathophysiological conditions, 5 including neurodegenerative disease 1 , drug addiction 2 , cancer 3 , and pain 4 . However, there are no 6 high-throughput functional assays for s1 receptor drug discovery. Here, we assessed high-7 throughput structure-based computational docking for discovery of novel ligands of the σ₁ 8 receptor. We screened a library of over 6 million compounds using the Schrödinger Glide 9 package, followed by experimental characterization of top-scoring candidates. 77% of tested 10 candidates bound s1 with high affinity (10-550 nM). These include compounds with high 11 selectivity for the s1 receptor compared to the genetically unrelated but pharmacologically 12 similar s2 receptor, as well as compounds with substantial cross-reactivity between the two 13 receptors. These results establish structure-based virtual screening as a highly effective platform 14 for σ₁ receptor ligand discovery. 15 16 17 18
oligomeric states [12] [13] [14] . Each monomer has an occluded ligand binding site containing Glu172 and 32
Asp126 11 , which are essential for ligand binding 15 . The first crystal structure of the human s1 33 receptor was solved with the receptor in complex with PD144418 at 2.5 Å resolution (PDB: 34 5HK1). Four other receptor-ligand complexes with ligands 4-IBP, haloperidol, NE-100, and (+)-35 pentazocine have been reported at crystallographic resolutions of 2.8-3. 1 Å 11,16 . As is typical of 36 s1 receptor ligands, these co-crystallized ligands are structurally divergent from one another. 37
Nonetheless, all five s1 receptor-ligand complexes solved to date share some key features, the 38 most notable of which is an essential electrostatic interaction between a basic amine moiety in 39 the ligand and the side chain of receptor residue Glu172 11, 16 . Given this constraint, we 40 hypothesized that the s1 receptor would be an ideal candidate for in silico ligand screening. 41
In silico screening uses software to estimate ligand binding energy, enabling efficient 42 prioritization of compounds while sampling a larger chemical space than is readily accessible to 43 experimental methods 17 . Schrödinger's Drug Discovery Platform Glide module 18,19 is a widely 44 used ligand docking software and is used as the preferred docking system by the structural 45 biology groups affiliated with SBGrid 20 . Glide converges upon optimally docked compounds by 46 sampling the ligand in various states and orientations within the user-defined binding site 18, 19 . 47
Candidate ligands that pass through initial space screens (i.e., those that are sterically capable of 48 fitting into the target site), are scored at increasing precision levels until the final Glide Score is 49 calculated, with lower Glide Scores indicating a higher predicted binding affinity 19 . Glide 50 docking has three precision levels, High Throughput Virtual Screening (HTVS), Standard 51 Precision (SP), and Extra Precision (XP). HTVS is a less stringent method that eliminates ligands 52 from the sample pool if their volume exceeds the binding site volume. SP and XP are slower, 53 more intensive algorithms that predict binding chemistry. In the case of the σ1 receptor, where no 54 high-throughput biological assays are available, computational docking is potentially useful for 55 identifying novel compounds that are chemically dissimilar to both one another and to known s1 56 receptor ligands. 57
Prior to docking experiments, a grid for Glide docking was established as a 10 Å cube 58 centered between the carboxylates of Glu172 and Asp126. In pilot docking test, this resulted in 59 known binders occupying a similar pose within the orthosteric site to that observed in crystal 60 structures. Enrichment plots were calculated to assess docking paradigms, following previously 61 reported approaches 17,21 . To compare enrichment with different approaches, we used 32 62 conformers of 15 known binders and 100,000 randomly selected eMolecules compounds of 63 similar molecular weight into a test subset (see Methods). The enrichment plots generated over 64 this subset confirmed that we were adequately predicting the binding mode of σ1 ligands in the 65 docking protocol. The docking algorithm recovered (scored) over 90% of known binders, with a 66 high proportion of the known binders being in the top 10% of scored compounds. Additionally, 67 through visual confirmation of Glide successfully docking the co-crystallized ligand in a similar 68 configuration as it is bound (Figure 2A ), the docking protocol demonstrated potential predictive 69 value. 70
Superimposition of the enrichment plots generated at the varying precision levels 71 demonstrated consistently higher recovery rates of known binders in flexible docking compared 72 to rigid docking. Extra precision flexible docking yielded the highest recovery rate (number of 73 known binders scored/total number of binders in subset tested) of known binders at 90.63%, 74 followed by standard precision flexible docking at just under 81.25%, extra precision standard 75 docking at 43.75%, and standard precision rigid docking at just below 33.33%. However, 76 flexible SP docking appeared better at recovering known binders early in the ranked database. It 77 is interesting that SP recovered more known binders quickly, as XP is considered to be the most 78 rigorous scoring paradigm, thus it would have been reasonable to see XP recover more known 79 binders overall and recover more in the top 10% of the tested ligands. The relationship between 80 SP and XP flexible and rigid docking is shown in Figure 2B . 81
In the docking experiment, compounds were selected from a starting library of over 6 82 million compounds through four sequential iterations of the docking protocol with increasing 83 precision levels. Approximately1.6 million compounds passed through high-throughput virtual 84 screening (HTVS) and went into SP, 71189 compounds from SP to XP, and 2625 compounds 85 from XP to Flexible XP docking (see Figure 2C ). From HTVS to SP all ligands that scored better 86 than the re-docked co-crystallized ligand were selected. For the transition from SP to XP, the 87 mean of all output scores in SP was found and all scores beyond 2 standard deviations from that 88 mean were selected, and for all other precision levels chose ligands further than 1 standard 89 deviation from the mean. 90 K-means clustering was applied to ligands based on volume occupied in binding site in 91 an attempt to select a unique set of ligands to experimentally validate. After collapsing many 92 sparse clusters, we found 3 main clusters with a total of 250 chemically and structurally diverse 93 compounds. After visual inspection of the docked structures, the top 100 compounds were 94 ranked based on glide score and the chemical plausibility of the docked pose. Of these, 17 95 representative compounds that were chemically divergent from one another and significantly 96 different from existing s1 receptor ligands were chosen for experimental assessment. 97
Among compounds purchased, 9 passed LC/MS inspection for purity and expected 98 molecular weight and were characterized further (Figures S1 and S2). Figure S3 depicts the 99 results from our initial screen of the compounds. Of the 9 compounds experimentally tested, 7 100 bound the s1 receptor with <1 µM affinity ( Table 1 and Figure S3B ). Compound 2 bound with 101 10 nM affinity ( Table 1) . Compounds 3, 4, 5 and 9 also bound with < 100 nM affinity, while 102 compounds 6 and 8 bound with 132 and 550 nM affinity respectively. 103
Though the s1 and s2 receptors are genetically unrelated, they have very similar 104 pharmacological profiles and development of selective compounds can be challenging 22 . We 105 reasoned that our structure-guided approach and the chemical diversity of our ligands might 106 allow the discovery of subtype-selective probes. The 9 compounds tested for σ1 receptor binding 107 were also tested for cross-reactivity with the σ2 receptor (Figures S3C and S3D, Table 1 ). Of the 108 compounds that bound well to s1 receptor, only compound 2 bound s2 with <100 nM affinity 109 (Table 1 ). The other compounds did not bind as well to σ2 in the initial screen as they did to σ1, 110 with most exhibiting >1 µM affinity for the s2 receptor. 111
To our knowledge, this work represents the first purely structure-based virtual screen on 112 the s1 receptor without the use of additional pharmacophore modeling. We found several ligands 113 that bound with high affinity and had good selectivity for the s1 receptor over the 114 pharmacologically similar s2 receptor. This work demonstrates that the s1 receptor is highly 115 amenable to in silico structure-based drug discovery, and that such approaches represent a viable 116 way to identify novel s1 receptor ligands at relatively low cost. 117
The σ1 receptor is an especially interesting target for virtual screening because of its 118 potential therapeutic relevance and the lack of functional assays suited to experimental high-119 throughput screening. Previous work has identified the minimal chemical features of σ1 ligands 120 to be a basic amine flanked by two hydrophobic regions, one that is 6-10 Å and another that is 121 2.5-3.9 Å 23 . Later work has refined this model, but the basic elements have remained 122 unchanged [24] [25] [26] [27] . 123
There have been previous attempts to design and discover σ1 receptor ligands through 124 computational pharmacophore modeling 24, 25 . These studies found high-affinity binders but were 125 limited to the discovery of compounds with very similar chemical features to reference ligands. 126
In another effort, a computationally predicted structural model of the σ1 receptor was developed 127 and used for ligand screening 28 . However, this model showed little similarity to the 128 experimentally determined σ1 receptor structure, and it only led to the identification of 129 compounds with poorer affinity than that of a reference ligand, indicating that it offered little if 130 any value in guiding ligand discovery. 131
More recent efforts have combined structural information from the s1 receptor crystal 132 structure with pharmacophore modelling or quantitative structure-affinity relationship (QSAR) 133 approaches 26, 27 . One recent report used the crystal structure of the s1 receptor bound to 134 PD144418 (PDB ID: 5HK1) to align 180 s1 receptor antagonists and develop a 3D-QSAR model 135 for s1 antagonists 26 . This model was able to accurately predict ligands that would bind the s1 136 receptor with high affinity from the Drugbank Database of FDA approved drugs, with the top 137 hits binding the receptor with 58 nM and 160 nM affinity 26 . Similarly, another recent study used 138 the same crystal structure to develop a predictive pharmacophore model, which was able to 139 accurately predict binders from a set of 3,707,672 conformers of 25,676 compounds previously 140 screened for s1 receptor affinity 27 . Interestingly, this study found that the pharmacophore model 141 derived from the s1 crystal structure was more accurate for this set of compounds than docking 142 into the structure directly using LibDock 27,29,30 . Neither of these models were used to identify 143 uncharacterized compounds, though some of the FDA approved drugs were not known to bind 144 s1 receptor previously 26, 27 . 145
Here, we show that Schrödinger Glide docking allows for the identification of novel s1 146 receptor ligands. Starting with a computational library of over 6 million compounds, we were 147 able to select only 9 for experimental characterization and still found 7 binders with sub-148 micromolar affinity, corresponding to a success rate of approximately 77%. This compares 149 favorably to other docking studies. Of 54 recent docking studies, only 8 had higher hit rates and 150 only 3 found compounds with better affinity than the best hit of 10 nM reported here, despite the 151 use of significantly larger screening libraries in some cases 31 . This may be because the s1 152 receptor is particularly well suited to computational docking. Most high-affinity ligands found to 153 date bind with only a single electrostatic interaction between a primary amine and Glu172, and affinity is likely driven largely by hydrophobic interactions and steric constraints. This relatively 155 simple binding mode may be easier to accurately predict by docking than more complex ones. 156
Indeed, constraining ligands to be docked near Glu172 and Asp126 was sufficient to successfully 157 find binders, without requiring a more complex pharmacophore model. 158
In addition to having high affinity for the σ1 receptor, most compounds tested here 159 exhibited high selectivity for the σ1 receptor over the pharmacologically similar σ2 receptor. Few 160 compounds bound to σ2 with sub-micromolar affinity, and almost all tested compounds had 161 higher affinity for the σ1 receptor than the σ2 receptor. For example, Compound 5 exhibited 81 162 nM affinity for the s1 receptor yet bound with >10 μM affinity to the σ2 receptor. In contrast, 163 compounds 2 and 6 showed high affinity for both σ1 and the σ2 receptor, indicating that non-164 selective ligands can also be identified by virtual screening even against just one receptor type. 165
While we focused here on the σ1 receptor, relatively few highly σ2 selective compounds are 166 currently available. The s2 structure may allow identification of highly σ2-selective ligands using 167 similar approaches to those described here, further expanding the suite of molecular tools 168 available for σ receptor research. 169 170
Materials and Methods 171
Computational Methods 172
Prior to docking, the σ1 receptor structure (PDB ID: 5HK1) was put through the Protein 173 Preparation Protocol 32 . This added hydrogens, removed co-crystallized water molecules, 174 enumerated bond orders, optimized the receptor's hydrogen bond network, and ran a restrained 175 minimization to alleviate backbone clashes within the receptor backbone. Additionally, Asp126 176 was protonated in our docking screens on the basis of its apparent hydrogen bond with Glu172 in 177 the crystal structure of the receptor 11 . 178
The eMolecules ligand library was prepared using the Ligand Preparation Protocol 32 to 179 generate three-dimensional geometries, assign proper bond orders, and generate accessible 180 tautomer and ionization states for the ligands prior to virtual screening 33 . 181
The grid generation protocol in Glide Docking defines the target area (binding site) for 182 each ligand to be tested within during the docking program. This was centered between the 183 carboxylates of Glu172 and Asp126 and was kept constant as the docking precision was 184 increased. Docking began with high throughput virtual screening (HTVS), in which all 185 compounds in the eMolecules library were tested. All ligands with Glide scores more favorable 186 than the score of the re-docked co-crystallized ligand PD144418 were put through standard 187 precision screening (SP). All compounds scoring better than 1 standard deviation from the mean 188 were tested in extra precision (XP), and the top 10% of XP ligands were put through flexible XP 189 docking, where the receptor backbone was given freedom to shift in order to fit ligands to the 190 orthosteric site. 191
To preform enrichment analysis similar to previous approaches 34 , a set of 15 known σ1 192 receptor binders were collected from the PDSP Ki Database 35 and put through the ligand 193 preparation protocol. These ligands were then tested in varying precision levels after being 194 merged with a set of 100,000 eMolecules ligands of similar weight to the known binders. The 195 average molecular weight of the known binders taken from the PDSP Ki Database is 351.07 196 g/mol, and the sample of ligands that were selected for enrichment with known binders had 197 molecular weights between 300 and 400 g/mol in an attempt to force Glide to focus on 198 differences in chemical composition rather than physicochemical descriptors. 199
Schrodinger Drug Discovery Platform installation was supported by SBGrid Consortium and all 200
data was generated and processed on SBGrid servers. 20 201 202
Recombinant receptor expression and preparation of Sf9 cell membranes 203
Membranes were prepared from Sf9 insect cells infected with baculovirus encoding either 204 recombinant σ1 or σ2 receptor, using a protocol adapted from that of Vilner et al., as previously 205 described 10, 11, 22 . Briefly, either the σ1 receptor or σ2 receptor, which was recently identified as 206 TMEM97 10 , were expressed in Sf9 cells using the pFastBac baculovirus expression system. Cells 207 were lysed by osmotic shock and membrane fractions were separated by repeated centrifugation 208 and washing steps, followed by dounce homogenization. Total protein content was quantified 209 using the BioRad DC protein assay, and membranes were stored in 100 μL aliquots at a 210 concentration of 3-10 mg/mL at -80 °C until use. 211
Screening docking hits for σ1 and σ2 receptor binding 212
Membrane radioligand binding assays were performed as described with slight 213 modifications 10,11,36 . All compounds were diluted to 10 μM in 50 mM Tris pH 8.0. Membrane 214 samples were also diluted and homogenized in 50 mM Tris pH 8.0 using a needle and syringe. A 215 total of 2.5 μg of protein was added to each well of a 96-well block in a final volume of 100 μL, 216 which also contained 1 μM of the compound and 10 nM of the appropriate radioligand ( 3 H (+)-217 pentazocine for the σ1 receptor, and 3 H DTG for the σ2 receptor). All reactions were performed 218 in triplicate. Haloperidol was used as a positive control, and buffer alone served as a negative 219 control. Samples were incubated at room temperature with shaking for 1.5 h. The reaction was 220 then terminated and samples were then applied to glass fiber filters (Merck Millipore) using a 221
Brandel cell harvester. Filters were soaked with 0.3% (w/v) polyethylimine prior to use. After 222 harvesting, filters were soaked overnight in scintillation vials containing 5 mL of Cytoscint 223 scintillation fluid and measured on a Beckman Coulter LS 6500 scintillation counter. 224
Saturation binding in Sf9 cell membranes. 225 3 H (+)-pentazocine and 3 H DTG saturation binding to Sf9 membranes respectively 226 expressing σ1 or σ2 receptor were determined using a saturation binding assay similar to that 227 described by Chu and Ruoho 36 ,which we have described previously 10,11 . The membranes (2.5 μg 228 and 0.5 μg total protein per reaction for σ1 and σ2 expressing membranes, respectively) were 229 incubated in a 100 μL reaction buffered with 50 mM Tris pH 8.0, containing 0-300 nM 3 H (+)-230 pentazocine for σ1 binding, or 0-300 nM 3 H DTG for σ2 receptor binding. In the σ2 receptor 231 binding assay, concentrations of 100 and 300 nM DTG were achieved by isotopic dilution to 232 minimize 3 H DTG expenditure. For both receptors, nonspecific binding was assayed by parallel 233 reactions containing 2 μM haloperidol. Reactions were incubated at 37 °C for 1.5 h and then 234 terminated, filtered, and measured as for the single-point binding described previously. All 235 reactions were performed in triplicate in a 96-well block. KD values were calculated using non-236 linear regression tools in Graphpad Prism. 237
Competition binding assays in Sf9 membranes. 238 3 H (+)-pentazocine or 3 H DTG competition curves testing the binding the docked 239 compounds to the σ1 and σ2 receptors respectively, were performed similarly to the protocol 240 described by Chu and Ruoho 36 ,with slight modifications we have used previously 10,11 . Briefly, 241
Sf9 insect membranes overexpressing either σ1 receptor (2.5 μg of total protein per reaction) or 242 σ2 receptor (0.5 --2.5 μg total protein per reaction) were incubated in a 100 μL reaction buffered 243 with 50 mM Tris pH 8.0, with the appropriate radioligand at a 10 nM concentration and eight 244 competing cold compound concentrations ranging from 10 pM -100 μM. Reactions were 245 incubated at 37 °C for 1.5 h to reach equilibrium, and then terminated by filtration as described 246 previously. Ki values were computed by directly fitting the data and using the experimentally 247 determined probe KD to calculate a Ki value, using the Graphpad Prism software. This process 248 implicitly uses a Cheng-Prusoff correction, so no secondary correction was applied. 249
LC/MS analysis of compound purity 250
Purchased compounds were analyzed on an Agilent QTOF 6530. Samples were separated 251 by reverse-phase HPLC (Agilent Extend C18 column 1.8 µM, 50 x 2.1 mm) at a flow rate of 0.3 252 mL min -1 in H2O with 0.1% formic acid for 15 min followed by a 5 min elution in 10-100% 253 Table 1 . Summary of experimental characterization of docked compounds. All affinity values are representative results from at least two independent experiments performed in triplicate. "N.D." indicates that the affinity was not determined.
